Top 30 Healthcare & Life Sciences PEF 2026

This report forms part of the Capital Ranking Healthcare & Life Sciences Private Equity series, which evaluates specialist private equity firms, healthcare-focused investment platforms, and life sciences-oriented private capital managers active across healthcare services, pharmaceutical services, medical products, diagnostics, healthcare technology, life sciences tools, outsourced healthcare infrastructure, and related regulated markets.

Healthcare and life sciences private equity firms provide capital to businesses operating within complex, highly regulated, and structurally important markets. Unlike generalist investors with occasional healthcare exposure, specialist firms often bring deeper understanding of reimbursement systems, clinical workflows, regulatory requirements, provider economics, pharmaceutical supply chains, medtech commercialization, diagnostics, healthcare IT, and patient-care infrastructure.

The category spans several distinct ownership models. Some firms build large provider, payer-services, and healthcare technology platforms through control-oriented buyouts and add-on acquisitions. Others invest in pharmaceutical services, life sciences tools, diagnostics, and medical products, where scientific credibility, quality systems, regulatory pathways, and specialized commercial capabilities are central to investment judgment. Growth-equity firms add a further dimension by supporting commercial-stage healthcare businesses before they reach conventional buyout scale.

Healthcare specialization does not eliminate investment risk. It changes the capabilities required to evaluate and manage that risk. The strongest firms combine sector knowledge with responsible governance, operating resources, management partnership, regulatory judgment, and the ability to improve access, quality, efficiency, or scientific infrastructure without weakening the integrity of care delivery.

This ranking identifies healthcare and life sciences private equity firms that demonstrate sustained sector focus, institutional credibility, active investment capability, and clear relevance within global private healthcare markets.

Market Overview

Healthcare private equity entered 2026 with renewed transaction momentum. Global healthcare deal value reached a record level in 2025, supported by large transactions, a recovery in sponsor-to-sponsor activity, and continued interest in providers, biopharma, healthcare IT, and outsourced healthcare infrastructure. Deal volume also remained historically strong across transaction sizes.

The recovery does not imply a less demanding investment environment. Competition for high-quality assets remains intense, valuations in defensible subsectors can be elevated, and financing conditions require more disciplined capital structures than in the low-rate period. Investors must underwrite a credible operating plan rather than depend on leverage, multiple expansion, or uncomplicated consolidation.

Healthcare services remain important, but the strongest investment cases increasingly depend on measurable improvements in productivity, patient access, clinical outcomes, site-of-care economics, or payer alignment. Physician groups and other provider platforms face particular scrutiny around clinician retention, reimbursement, governance, quality, and the sustainability of acquisition-led growth.

Life sciences and pharmaceutical services provide a different source of opportunity. Contract research, contract development and manufacturing, commercialization services, specialty distribution, laboratory infrastructure, diagnostics, and life sciences tools allow investors to participate in scientific innovation without assuming the full binary risk of drug discovery. These businesses nevertheless require careful assessment of customer concentration, quality systems, capacity utilization, scientific relevance, and regulatory compliance.

Healthcare IT continues to increase its share of transaction activity. Providers, payers, pharmaceutical companies, and medical-product businesses require better data infrastructure, workflow software, cybersecurity, revenue-cycle tools, utilization management, and automation. Artificial intelligence is broadening this opportunity, but it also increases the importance of data rights, clinical validation, interoperability, model governance, and proof of measurable customer value.

Industry Trend — 2026

In 2026, healthcare private equity is being shaped by a combination of larger transactions, sharper regulatory attention, and greater operational sophistication. Capital remains available for differentiated assets, but investment committees are placing more weight on downside protection, reimbursement durability, compliance, management quality, and the ability to execute a clearly defined value-creation plan.

The sector is also becoming more global. North America remains the largest market for healthcare private equity, while Europe offers substantial opportunities across pharmaceutical services, medtech, diagnostics, healthcare providers, and outsourced clinical infrastructure. Asia is becoming increasingly important through healthcare delivery, life sciences manufacturing, biotechnology, medical technology, and the expansion of private healthcare systems.

The announced combination of GHO Capital and CBC Group illustrates this globalization. Subject to completion, the transaction is intended to connect European, North American, and Asian healthcare investment capabilities within a single specialist platform. It also reflects a wider industry trend toward scale, multiple capital strategies, and cross-border access to healthcare innovation.

Artificial intelligence is moving from an investment theme to an operating requirement. Healthcare investors are evaluating AI-enabled clinical workflows, administrative automation, coding, revenue-cycle management, drug-development tools, and patient engagement. They are also developing internal capabilities to help portfolio companies prioritize implementation. The central challenge is to distinguish useful, governed applications from products whose economics, clinical validity, or competitive protection remain uncertain.

Healthcare segment	2026 investment rationale	Principal diligence and ownership priorities
Provider and specialty-care platforms	Demographic demand, care migration, fragmentation, and opportunities to improve access and operating consistency	Clinical quality, clinician retention, reimbursement, referral integrity, compliance, local market density, and patient outcomes
Healthcare IT and tech-enabled services	Demand for workflow efficiency, interoperability, automation, analytics, and lower administrative cost	Data rights, cybersecurity, customer retention, implementation burden, AI governance, recurring revenue quality, and measurable return on investment
Pharmaceutical services	Outsourcing across research, development, manufacturing, commercialization, and supply-chain functions	Customer concentration, quality systems, regulatory history, capacity utilization, technical differentiation, and long-duration client relationships
Life sciences tools and diagnostics	Scientific innovation, laboratory automation, precision medicine, and recurring demand for research and testing infrastructure	Scientific relevance, installed base, consumables mix, reimbursement, regulatory pathway, intellectual property, and research-budget sensitivity
Medical products and medtech	Aging populations, procedural growth, care-setting shifts, and demand for more effective or less invasive treatment	Clinical evidence, regulatory clearance, physician adoption, manufacturing quality, procurement economics, and product-concentration risk
Payer and benefits infrastructure	Need to manage cost, utilization, navigation, pharmacy expenditure, and population health	Outcome evidence, regulatory exposure, employer and payer concentration, member engagement, savings validation, and incentive alignment
Consumer health and wellness	Preventive care, self-directed healthcare spending, and growing consumer engagement with health	Clinical credibility, brand durability, customer-acquisition cost, claims substantiation, channel concentration, and regulatory compliance
Healthcare distribution and supply chain	Essential role in product availability, specialty logistics, procurement, and resilient care delivery	Margin structure, working capital, supplier concentration, inventory control, quality assurance, and operational resilience

The strongest healthcare investment firms therefore combine specialization with institutional flexibility. They must understand how science, regulation, technology, reimbursement, labor, and care quality interact, while remaining capable of financing growth, professionalizing organizations, supporting management teams, and managing complex exits.

Methodology — Core Eligibility Criteria

To ensure structural consistency within the category, firms considered for this ranking were evaluated according to the following eligibility conditions:

• Operates as a healthcare, life sciences, healthcare services, healthcare technology, medical products, diagnostics, pharmaceutical services, or related healthcare private equity or growth-equity platform
• Provides buyout, control-oriented, recapitalization, or institutionally significant growth capital to healthcare and life sciences businesses
• Demonstrates visible activity in healthcare services, healthcare IT, pharma services, medtech, diagnostics, life sciences tools, outsourced healthcare infrastructure, or related regulated markets
• Maintains sector-specific investment judgment, operating resources, regulatory understanding, scientific expertise, or healthcare value-creation capability
• Exhibits active market presence, operational traceability, and institutional credibility
• Retains a meaningful standalone institutional identity within healthcare and life sciences private markets
• Shows a sustained commitment to healthcare rather than incidental exposure through a broad generalist portfolio

Large generalist private equity platforms, venture-only investors, public-equity managers, inactive firms, and firms whose healthcare exposure could not be evaluated separately were excluded or de-emphasized. Generalist firms with a substantial, long-standing, and institutionally identifiable healthcare franchise remained eligible.

Methodology — Ranking Factors

Firms included in the ranking were evaluated using a combination of qualitative and structural considerations. Key factors include:

• Healthcare and life sciences private equity track record
• Strength, continuity, and breadth of healthcare-sector specialization
• Institutional scale and credibility across fundraising and investment cycles
• Experience across healthcare services, life sciences, pharmaceutical services, medical products, diagnostics, healthcare IT, and healthcare technology
• Ability to support platform formation, operational improvement, management professionalization, and acquisition-led expansion
• Regulatory, reimbursement, clinical, scientific, and quality-system understanding
• Portfolio operating resources and sector-specific executive networks
• Relevance across buyout, growth equity, recapitalization, founder transition, corporate carve-out, and platform-building strategies
• Capacity to support responsible care delivery, patient access, quality, efficiency, or healthcare innovation
• Geographic reach and ability to manage cross-border healthcare investments
• Current investment activity and continuity of capital deployment
• Independence or meaningful standalone institutional identity
• Ability to manage financing, capital structure, governance, and exit complexity
• Long-term influence and credibility within healthcare and life sciences private markets

The objective of the ranking is to identify firms that maintain sustained relevance within the healthcare and life sciences private equity ecosystem rather than to compare short-term fund performance.

The ranking universe consisted of approximately 120 healthcare and life sciences investment firms, from which 30 institutions were selected for inclusion.

Tier classifications reflect relative institutional positioning and do not represent investment recommendations, fund-performance rankings, or endorsements of any investment product.

Company Profiles and Further Reference

Firm names appearing in this ranking are linked to their corresponding profiles in The Economy Wiki for companies, where available. These profiles provide additional background on each organization, including its principal activities, sector focus, market positioning, leadership, corporate information, and related rankings and analysis across The Economy Network.

The Economy Wiki profiles are maintained as editorial reference pages and may be updated as new public information becomes available.

---

Tier I — Leading Healthcare & Life Sciences Private Equity Platforms

Welsh, Carson, Anderson & Stowe

• Headquarters: New York, United States
• Founded: 1979

Welsh, Carson, Anderson & Stowe is one of the most established private equity firms with a sustained focus on healthcare and technology. Its healthcare investment history spans provider services, payer services, healthcare IT, outsourced healthcare infrastructure, and other businesses supporting the delivery and financing of care.

WCAS has repeatedly used platform-building strategies in fragmented healthcare markets. This model requires more than acquisition financing: portfolio companies need management depth, integration capability, compliance systems, technology investment, and a coherent approach to clinical or service quality as they expand.

The firm’s longevity provides experience across changing reimbursement systems, regulatory cycles, financing conditions, and models of healthcare delivery. Its executive network and institutional resources also support leadership recruitment, strategic acquisitions, and organizational development.

WCAS fits Tier I because healthcare has remained central to its identity over multiple decades. Its track record, institutional scale, and influence on the development of healthcare services and technology investing make it a foundational category benchmark.

Patient Square Capital

• Headquarters: Menlo Park, United States
• Founded: 2020

Patient Square Capital is a dedicated healthcare investment firm built to deploy substantial and flexible capital across the healthcare ecosystem. Despite its relatively recent formation, the firm has developed approximately $19 billion in assets under management and participates in transactions requiring large-scale equity, sector knowledge, and long-duration support.

Its mandate spans established healthcare organizations, growth companies, products, services, and technologies. Patient Square has pursued major take-private and strategic transactions while emphasizing a patient-centered investment philosophy and the capital intensity required to support healthcare businesses through development, commercialization, and organizational transformation.

The firm’s team combines investment professionals with healthcare executives and sector specialists. This structure is relevant in a market where regulatory change, scientific complexity, care quality, and operating execution can materially affect investment outcomes.

Patient Square fits Tier I because it has rapidly become one of the largest healthcare-only investment platforms. Its scale, transaction capability, sector breadth, and dedicated institutional model establish it as a leading force in contemporary healthcare private equity.

GHO Capital

• Headquarters: London, United Kingdom
• Founded: 2014

GHO Capital is a specialist healthcare investment firm focused on building businesses across healthcare services, pharmaceutical and life sciences services, medtech, diagnostics, and related healthcare markets. Its investment model combines sector research, operating resources, and transatlantic development.

The firm has grown into one of Europe’s largest dedicated healthcare investment platforms. Its portfolio reflects the importance of outsourced pharmaceutical infrastructure, medical products, patient services, and healthcare businesses that can scale across national markets.

In May 2026, GHO and CBC Group announced an intended combination that would create a healthcare-focused investment platform with more than $21 billion in combined assets under management. The transaction is expected to close after customary approvals, so GHO remains separately evaluated in this edition.

GHO Capital fits Tier I because it combines dedicated healthcare specialization, substantial institutional scale, transatlantic reach, and a clear record of supporting internationally oriented healthcare companies.

CBC Group

• Headquarters: Singapore
• Founded: 2014

CBC Group is a healthcare-dedicated investment firm with a major presence across Asia. Its platform spans private equity, private credit, real estate, and other healthcare-related capital strategies, with investment exposure across biopharma, life sciences, medical technology, care delivery, and pharmaceutical infrastructure.

The firm’s Asian network gives it a distinctive position in markets where healthcare demand, domestic innovation, manufacturing capability, and private care infrastructure are developing rapidly. CBC can support companies seeking regional scale while connecting Asian healthcare businesses with global capital and commercial relationships.

CBC’s announced combination with GHO Capital is intended to connect investment capabilities across Asia-Pacific, Europe, and North America. Until the transaction closes, CBC continues to operate as a separately identifiable platform and is assessed on that basis.

CBC Group fits Tier I because of its dedicated healthcare identity, approximately $10.8 billion in assets under management, regional influence, and importance in connecting Asian healthcare markets with the wider global investment ecosystem.

WindRose Health Investors

• Headquarters: New York, United States
• Founded: 2000

WindRose Health Investors is a healthcare-focused private equity firm investing principally in healthcare services and technology-enabled businesses that seek to improve quality, efficiency, and access. Its portfolio spans provider, payer, pharmaceutical, clinical, and administrative infrastructure.

The firm has expanded substantially while maintaining a sector-specific mandate. The closing of its seventh fund at $2.6 billion brought assets under management to approximately $7 billion, giving WindRose the capital base to pursue larger platforms while continuing to apply a focused healthcare-services model.

WindRose has also developed a dedicated technology and artificial-intelligence capability to help portfolio companies identify and implement operational projects. This reflects the increasing need for healthcare investors to support data, automation, cloud, cybersecurity, and AI execution rather than treat technology as a purely external diligence topic.

WindRose fits Tier I because it combines more than two decades of healthcare investing with current institutional scale, a clearly defined services strategy, and visible operating resources aligned with the direction of healthcare delivery.

---

Tier II — Established Healthcare & Life Sciences Private Equity Firms

(Alphabetical order)

Ampersand Capital Partners

• Headquarters: Boston, United States
• Founded: 1988

Ampersand Capital Partners is a healthcare and life sciences-focused private equity firm with long-standing experience in middle-market investing. Its principal areas include life sciences tools, diagnostics, pharmaceutical services, contract development and manufacturing, laboratory products, and related healthcare technologies.

The firm’s life sciences orientation provides an important counterweight to healthcare lists dominated by provider services. Businesses serving research, development, testing, and production require specialized assessment of scientific relevance, quality systems, customer relationships, regulatory requirements, and technical differentiation.

Ampersand typically partners with companies that possess an established commercial foundation but require capital, strategic guidance, acquisition support, or operational resources to scale. Its sector network and repeated experience across technical healthcare markets support informed platform development.

Ampersand fits Tier II because it is an established specialist with a clear standalone identity, sustained life sciences relevance, and a differentiated record in the infrastructure supporting scientific and medical innovation.

ArchiMed

• Headquarters: Lyon, France
• Founded: 2014

ArchiMed is a healthcare-focused private equity firm investing globally in small, mid-sized, and selected larger healthcare businesses. Its activity spans life sciences tools, diagnostics, medtech, pharmaceutical services, healthcare services, and other regulated subsectors.

The firm applies a dedicated healthcare model supported by sector specialists and operating resources. This structure is valuable in businesses where product quality, scientific knowledge, regulatory execution, international commercialization, and operational scaling must be managed together.

ArchiMed also brings substantial European representation to the ranking. Its portfolio demonstrates that healthcare private equity extends beyond U.S. provider consolidation into medical technology, diagnostics, pharmaceutical infrastructure, and specialized healthcare manufacturing.

ArchiMed fits Tier II because it combines category purity, active international development, and a recognizable healthcare investment franchise. Its breadth across company sizes and subsectors gives it a strong position among established specialists.

Avista Healthcare Partners

• Headquarters: New York, United States
• Founded: 2005

Avista Healthcare Partners is a private equity firm focused on healthcare businesses across pharmaceuticals, medical products, healthcare services, outsourced healthcare infrastructure, and related regulated markets.

The firm invests in companies where sector expertise and operating support can assist product expansion, commercial development, organizational improvement, and strategic acquisitions. Its portfolio has included businesses requiring detailed understanding of pharmaceutical supply chains, medical-product markets, healthcare customers, and regulatory quality.

Avista’s healthcare-only institutional identity distinguishes it from broad private equity platforms. It can apply a consistent sector framework across control investments and growth situations while working with management teams on the specific constraints of regulated healthcare markets.

Avista fits Tier II because it is an established, active, and clearly identifiable healthcare private equity firm with meaningful experience across products, services, and pharmaceutical infrastructure.

Frazier Healthcare Partners

• Headquarters: Seattle, United States
• Founded: 1991

Frazier Healthcare Partners is a healthcare-focused investment firm active across growth buyouts and life sciences. Its investment history covers healthcare services, pharmaceutical services, medical products, therapeutics, and growth-oriented healthcare businesses.

The firm’s dual strategy gives it exposure to both operational healthcare companies and innovation-driven life sciences markets. This is increasingly relevant as healthcare services, technology, pharmaceutical infrastructure, and scientific development become more interconnected.

Frazier’s growth-buyout activity emphasizes scalable platforms, management partnership, operational improvement, and sector knowledge. Its life sciences capabilities add scientific and clinical perspective, enabling the wider organization to assess healthcare opportunity through more than a traditional services framework.

Frazier fits Tier II because it combines a long institutional history, a dedicated healthcare identity, and credible capabilities across both operating healthcare businesses and life sciences innovation.

GTCR

• Headquarters: Chicago, United States
• Founded: 1980

GTCR is a private equity firm with a substantial healthcare franchise across healthcare services, medical products, pharmaceuticals, life sciences, healthcare IT, and technology-enabled businesses. The firm is known for its strategy of partnering with experienced executives to build companies around defined investment themes.

This management-led model is especially relevant in fragmented healthcare markets. Successful platform formation often depends on recruiting credible leadership, establishing compliance and operating systems, completing disciplined acquisitions, and aligning growth with customer or patient needs.

Although GTCR invests beyond healthcare, its sector record is deep and sustained. The firm has repeatedly backed healthcare executives and platforms through different market cycles, giving it institutional relevance beyond that of a generalist firm making occasional healthcare investments.

GTCR fits Tier II because its healthcare track record, executive partnership model, capital resources, and platform-building capability establish it as a major participant in healthcare private equity.

Linden Capital Partners

• Headquarters: Chicago, United States
• Founded: 2004

Linden Capital Partners is a dedicated healthcare private equity firm investing across healthcare services, medical products, healthcare IT, life sciences, and related businesses. Its exclusive healthcare focus gives it a clear sector identity and consistent investment framework.

The firm works with management teams, operating partners, and industry executives to support commercial development, acquisition strategies, organizational improvement, and growth. This model is suited to healthcare businesses where reimbursement, regulation, product quality, and customer relationships require specialized judgment.

Linden’s network across healthcare executives, intermediaries, and subsector specialists supports sourcing and diligence in markets where technical complexity can create both competitive advantage and hidden risk.

Linden fits Tier II because it is one of the most recognized dedicated healthcare private equity firms in the middle market. Its focused model, institutional continuity, and experience across multiple healthcare verticals support a strong established-tier position.

Martis Capital

• Headquarters: San Francisco, United States
• Founded: 2011

Martis Capital is a healthcare-focused private equity firm investing in middle-market companies across healthcare services, healthcare technology, consumer health, products, diagnostics, and related sectors.

The firm targets businesses addressing challenges in care delivery, patient access, healthcare operations, and system efficiency. These markets often require investors to understand clinical workflows, payer relationships, regulatory context, technology adoption, and the organizational demands of scaling.

Martis emphasizes partnership with founders and management teams. Its flexible approach can support control investments, recapitalizations, and growth situations where existing leaders seek capital and sector-specific resources without losing the operating identity of the business.

Martis Capital fits Tier II because it has developed a visible healthcare franchise, a broad but coherent subsector mandate, and a credible middle-market position supported by dedicated healthcare expertise.

Quadria Capital

• Headquarters: Singapore
• Founded: 2012

Quadria Capital is a healthcare-focused private equity firm investing across South and Southeast Asia. Its portfolio includes healthcare delivery, life sciences, medical technology, pharmaceutical services, and associated healthcare infrastructure.

The firm’s regional mandate addresses markets where rising incomes, demographic change, underdeveloped care capacity, and expanding private healthcare demand create substantial growth opportunities. These opportunities also require careful management of affordability, clinical quality, governance, and country-specific regulation.

Quadria combines investment teams with a network of healthcare operating executives who support management, cross-border expansion, governance, and value creation. Its funds and portfolio provide meaningful exposure to India, Vietnam, Indonesia, Malaysia, Singapore, and other regional markets.

Quadria Capital fits Tier II because it is one of Asia’s most established dedicated healthcare investors, with more than $4 billion under management, an active regional platform, and clear relevance to the development of healthcare systems across emerging Asian markets.

Shore Capital Partners

• Headquarters: Chicago, United States
• Founded: 2009

Shore Capital Partners is a lower-middle-market private equity firm with extensive activity in healthcare alongside other selected sectors. Its healthcare investments span provider services, products, distribution, behavioral health, veterinary services, and related markets.

The firm is known for building platforms from smaller businesses in fragmented sectors. This strategy requires management recruitment, compliance infrastructure, local market development, acquisition integration, and the introduction of systems capable of supporting rapid organizational growth.

Shore’s healthcare franchise has increased in scale while retaining an emphasis on founder-led and lower-middle-market companies. Its high level of transaction activity gives it visibility across subsectors that may be too small or operationally intensive for larger healthcare funds.

Shore fits Tier II because healthcare represents a major and sustained part of its investment platform. Its sourcing reach, platform-building model, and current institutional scale make it an important participant in the U.S. healthcare private equity market.

Water Street Healthcare Partners

• Headquarters: Chicago, United States
• Founded: 2005

Water Street Healthcare Partners is a healthcare-focused private equity firm investing across healthcare services, medical products and diagnostics, and pharmaceutical and life sciences businesses.

The firm’s strategy centers on building healthcare companies through organic development, acquisitions, product expansion, and commercial improvement. It works with management teams seeking to establish stronger market positions, enter adjacent categories, broaden distribution, or develop internationally.

Water Street’s healthcare-only orientation supports detailed sector relationships and pattern recognition. Its portfolio spans areas where operating capability, product knowledge, regulatory quality, and customer access can be more important than financial engineering.

Water Street fits Tier II because it is an established specialist with a clear institutional identity, visible market activity, and a sustained record of building companies across several important healthcare verticals.

---

Tier III — Specialist Healthcare & Life Sciences Private Equity Firms

(Alphabetical order)

1315 Capital

• Headquarters: Philadelphia, United States
• Founded: 2014

1315 Capital is a private equity firm exclusively focused on growth-stage healthcare companies. Its investment areas include healthcare services, pharmaceutical and medtech products, outsourced pharmaceutical and medtech services, and health and wellness.

The firm partners with commercial-stage businesses that have established products or services but require capital and operating support to accelerate growth. Its model is relevant to companies that may be beyond venture financing yet remain too early or specialized for traditional large-cap buyouts.

1315 supports portfolio companies through management resources, strategic initiatives, operational improvement, and commercial expansion. Its experience across products, services, and outsourcing provides useful breadth within a healthcare-only mandate.

1315 Capital fits Tier III because it is an increasingly developed healthcare growth platform with more than $1 billion under management, a clear specialist identity, and strong alignment with commercial-stage healthcare company building.

Apposite Capital

• Headquarters: London, United Kingdom
• Founded: 2006

Apposite Capital is a specialist European healthcare and life sciences investor focused on small and medium-sized businesses. Its activity spans healthcare providers, digital health, medical products, devices, pharmaceuticals, and life sciences services.

The firm often acts as a company’s first institutional investor, supporting founder transitions, management buyouts, growth capital, and buy-and-build strategies. This position requires a hands-on approach to governance, leadership recruitment, digitalization, commercial development, and operating professionalization.

Apposite also incorporates healthcare impact into its ownership model, with attention to quality, access, innovation, and the expansion of healthcare capacity. This is especially relevant in smaller care and medical-product businesses where operational improvement can directly affect service delivery.

Apposite Capital fits Tier III because it is an established pan-European specialist with a focused SME mandate and a differentiated role in scaling healthcare businesses from founder-led organizations into institutional platforms.

DW Healthcare Partners

• Headquarters: Toronto, Canada, and Park City, United States
• Founded: 2002

DW Healthcare Partners is a healthcare-focused private equity firm investing in middle-market companies across healthcare services, medical products, diagnostics, pharmaceutical services, and related sectors.

The firm combines control-oriented investing with flexibility to support management teams and founders through ownership transitions. Its value-creation model emphasizes organic growth, strategic acquisitions, operating support, and capital structures that do not depend on excessive leverage.

DWHP brings useful North American breadth to the category through its Canadian and U.S. presence. Its six-fund platform, more than $2.7 billion in assets under management, and extensive record of platform and add-on investments demonstrate sustained institutional development.

DW Healthcare Partners fits Tier III because it is a long-standing and active healthcare specialist with meaningful scale, while its middle-market geographic and transaction focus remains more concentrated than the firms in the upper tiers.

Eir Partners

• Headquarters: Miami, United States
• Founded: 2015

Eir Partners is a healthcare technology-focused private equity firm investing in health-tech and technology-enabled healthcare services businesses.

The firm targets companies using software, data, workflow infrastructure, and specialized services to address operational challenges across healthcare. Relevant areas include payer and provider technology, patient engagement, analytics, administrative infrastructure, and tools that improve the efficiency of healthcare delivery.

Healthcare technology requires specialized diligence because recurring revenue alone does not establish durability. Investors must assess integration requirements, data access, regulatory exposure, customer concentration, cybersecurity, and whether a product produces measurable clinical or financial value.

Eir Partners fits Tier III because it is a younger and narrower platform than the established healthcare buyout firms, but its concentrated health-tech mandate provides valuable exposure to one of the most important areas of current healthcare investment.

EW Healthcare Partners

• Headquarters: New York and Palo Alto, United States
• Founded: 1985

EW Healthcare Partners is a healthcare investment firm with a long history across pharmaceuticals, biotechnology, medical devices, diagnostics, and healthcare services. The firm developed from the Essex Woodlands platform and maintains a healthcare-focused growth-equity identity.

Its strategy is particularly relevant to commercial-stage businesses that require capital to expand products, build sales capabilities, navigate regulatory milestones, or scale internationally. These companies often combine scientific or clinical innovation with the execution demands of an operating business.

EW’s long sector history provides perspective across healthcare innovation cycles and capital-market conditions. Its portfolio orientation adds product and life sciences depth to a category that might otherwise lean too heavily toward healthcare-service buyouts.

EW Healthcare Partners fits Tier III because it is an experienced healthcare growth investor with a differentiated products-and-innovation mandate, although its investment model is more growth-oriented and concentrated than conventional control private equity.

Great Point Partners

• Headquarters: Greenwich, United States
• Founded: 2003

Great Point Partners is a healthcare investment firm focused on growing companies across the biopharmaceutical supply chain, healthcare IT-enabled services, healthcare services, and medical-device manufacturing.

The firm targets profitable or commercially established businesses operating in specialized markets where customer relationships, regulatory standards, technical expertise, and management quality are essential. These characteristics are common in outsourced life sciences and healthcare infrastructure.

Great Point combines private equity with sector research and operational support. Its mandate allows it to invest across service, technology, and product-related businesses while maintaining a consistent healthcare focus.

Great Point Partners fits Tier III because it is an active and credible specialist with particular strength in life sciences-adjacent services and lower-middle-market healthcare growth.

HealthEdge Investment Partners

• Headquarters: Tampa, United States
• Founded: 2005

HealthEdge Investment Partners is a lower-middle-market private equity firm focused exclusively on healthcare businesses. It invests in founder-led and established companies where operating experience and healthcare relationships can support growth.

Smaller healthcare businesses frequently need more than transaction capital. They may require stronger financial systems, management depth, commercial strategy, compliance infrastructure, technology investment, and a disciplined approach to acquisitions.

HealthEdge’s focused mandate allows it to work closely with management teams through these institutionalization steps. Its portfolio reflects the role of specialist investors in subsectors that are too small or operationally specific for larger funds.

HealthEdge Investment Partners fits Tier III because it is a long-standing healthcare-only investor with a hands-on lower-middle-market model and a clearly defined role within the specialist segment.

InTandem Capital Partners

• Headquarters: New York, United States
• Founded: 2011

InTandem Capital Partners is a healthcare-focused private equity firm investing in lower-middle-market services businesses. Its portfolio has included provider platforms, specialty care, payer-related services, and other companies positioned to improve healthcare delivery.

The firm combines capital with operating resources and healthcare executive relationships. Its strategy often involves working with management teams to build regional or national platforms through organic development, acquisitions, and stronger operating infrastructure.

Site-of-care changes and demand for specialized outpatient services create opportunities for this model, but they also require disciplined attention to clinician alignment, reimbursement, regulatory compliance, patient experience, and local market execution.

InTandem Capital Partners fits Tier III because it is an established healthcare services specialist with a clear platform-building identity, while its scale and subsector range remain more concentrated than those of the upper-tier firms.

MVM Partners

• Headquarters: Boston, United States, and London, United Kingdom
• Founded: 1997

MVM Partners is a healthcare investment firm supporting high-growth businesses across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and life sciences tools.

The firm operates across the United States and Europe and focuses on companies with differentiated products, technologies, or scientific capabilities addressing meaningful unmet needs. Its investments commonly require judgment regarding intellectual property, regulatory pathways, clinical evidence, commercialization, and strategic exit markets.

MVM’s transatlantic model helps portfolio companies access management networks, customers, capital, and potential strategic partners in two major healthcare innovation regions. Its concentrated approach allows close engagement with management teams.

MVM Partners fits Tier III because it brings long-standing life sciences and medtech growth expertise to the ranking. Its mandate is narrower and more innovation-oriented than conventional buyout private equity, but institutionally significant within healthcare growth capital.

Questa Capital

• Headquarters: Washington, D.C., and San Francisco, United States
• Founded: 2016

Questa Capital is a healthcare-focused growth-equity firm investing in healthcare services, healthcare technology, and medical devices.

The firm backs commercial-stage companies with scalable business models and products or services intended to improve care, efficiency, safety, or patient experience. Its concentrated investment approach gives each portfolio company meaningful institutional attention.

Questa’s focus sits between venture capital and traditional buyouts. Portfolio companies generally possess market validation but require capital and strategic support to accelerate growth, develop management teams, expand geographically, or reach the scale needed for a strategic or sponsor-backed exit.

Questa Capital fits Tier III because it has developed a credible healthcare-only growth platform with approximately $1 billion under management and clear specialization across services, technology, and devices.

Revelstoke Capital Partners

• Headquarters: Denver, United States
• Founded: 2013

Revelstoke Capital Partners is a healthcare-focused private equity firm investing in healthcare services, healthcare technology, and health and wellness companies.

The firm targets businesses that can scale through organic development, operating improvement, and add-on acquisitions. Its portfolio reflects opportunities in fragmented healthcare markets where stronger systems, management resources, and geographic expansion can create more durable organizations.

Revelstoke’s model is particularly relevant to services and technology-enabled platforms addressing access, efficiency, and specialized care delivery. These investments require careful integration and attention to quality as organizations increase in size.

Revelstoke Capital Partners fits Tier III because it is an active specialist with a clear healthcare mandate and visible platform-building experience, while remaining younger and more concentrated than the established firms in Tier II.

RoundTable Healthcare Partners

• Headquarters: Lake Forest, United States
• Founded: 2001

RoundTable Healthcare Partners is an operating-oriented private equity firm focused exclusively on healthcare. Its principal sectors include medical products, specialty pharmaceuticals, healthcare distribution, and outsourced services.

The firm’s products-and-services orientation requires capabilities in manufacturing, quality systems, supply chains, distribution relationships, regulatory compliance, and commercial execution. These demands differ materially from those of provider-services investing.

RoundTable supports portfolio companies through operational improvement, strategic expansion, and acquisition-led growth. Its long-standing healthcare-only model provides experience across economic, regulatory, and product cycles.

RoundTable Healthcare Partners fits Tier III because it is a credible and enduring specialist with useful exposure to healthcare products and distribution, although its institutional footprint is more concentrated than that of the larger dedicated platforms.

Signet Healthcare Partners

• Headquarters: New York, United States
• Founded: 1998

Signet Healthcare Partners is a healthcare growth-equity firm focused on commercial-stage companies, particularly in pharmaceuticals, medical devices, diagnostics, and related healthcare products.

The firm provides capital to businesses that are generating revenue or approaching commercialization. These companies need specialized support around product launch, regulatory strategy, market access, manufacturing, distribution, and the development of commercial organizations.

Signet adds important product and life sciences representation to the ranking. Its model differs from control-oriented healthcare services investing because value creation depends more directly on product adoption, clinical utility, quality, and commercial execution.

Signet Healthcare Partners fits Tier III because it is a focused and experienced healthcare growth investor whose narrower scale and product-oriented mandate support specialist-tier classification.

Truehelm

• Headquarters: Bloomington, United States
• Founded: 2012

Truehelm is a healthcare-focused private equity firm investing in healthcare IT and technology-enabled services. The firm adopted the Truehelm name in 2026 after operating as TT Capital Partners.

Its strategy centers on companies that improve how healthcare is delivered, managed, or financed through software, data, workflow tools, and specialized services. These businesses can benefit from strong industry demand but must demonstrate durable customer value, integration capability, and defensible market positioning.

Truehelm combines healthcare investment experience with operating and financial-services knowledge. Its focus is especially relevant as payers, providers, and other healthcare organizations seek more efficient administrative and clinical infrastructure.

Truehelm fits Tier III because it is a focused, current, and institutionally developed health-tech investor with approximately $1 billion under management. Its narrower sector and transaction mandate distinguish it from broader healthcare private equity platforms.

Vesey Street Capital Partners

• Headquarters: New York, United States
• Founded: 2014

Vesey Street Capital Partners is a private equity firm specializing in lower-middle-market healthcare services businesses.

The firm pursues buyouts and platform investments in sectors where operating expertise, healthcare relationships, and management partnership can support growth. It focuses on businesses that may be too specialized or operationally complex for broad generalist investors.

Lower-middle-market healthcare platforms frequently require investment in leadership, systems, compliance, technology, and acquisition integration before they can achieve institutional scale. Vesey Street’s sector orientation is designed to support that transition.

Vesey Street Capital Partners fits Tier III because it is an active and clearly identifiable healthcare services specialist with a focused lower-middle-market role.

---

Remarks

Healthcare and life sciences private equity remains one of the most important specialist segments of global private markets. The category provides exposure to demographic demand, care-delivery transformation, medical innovation, pharmaceutical infrastructure, diagnostics, healthcare technology, and the systems required to make healthcare more accessible and efficient.

The 2026 environment rewards firms that can translate sector knowledge into responsible and measurable operating improvement. Capital scale can support larger transactions and longer investment horizons, but it does not replace judgment regarding reimbursement, clinical quality, regulation, scientific relevance, management, or patient impact.

The firms recognized in this ranking represent different forms of specialization. Some build provider and payer-services platforms; others focus on medical products, pharmaceutical services, life sciences tools, or healthcare technology. Growth investors support commercial-stage innovation, while regionally focused firms provide local knowledge across North America, Europe, and Asia.

The ranking emphasizes sustained healthcare commitment, institutional credibility, active investment capability, sector-specific resources, and publicly traceable operating platforms. Tier classification reflects relative positioning within healthcare and life sciences private equity and does not represent investment advice, fund-performance evaluation, or endorsement of any investment product.

---

Recognition

Inclusion in the Top 30 Healthcare & Life Sciences PEF 2026 ranking is an editorial determination of The Economy Rankings and is independent of licensing, advertising, sponsorship, or other commercial participation.

Ranked organizations may factually refer to their inclusion in the ranking in their own communications. When describing the result, firms should accurately reflect the tier structure and methodology used in the published ranking.

How the ranking should be interpreted

• Tier I represents the Top 5 firms, and the published order within Tier I reflects the ranking order.
• Tier II represents firms ranked within the Top 15, following Tier I. Firms within Tier II are displayed alphabetically; their displayed order should therefore not be interpreted as an individual numerical ranking.
• Tier III represents firms ranked within the Top 30, following Tiers I and II. Firms within Tier III are also displayed alphabetically, and their displayed order should not be interpreted as an individual numerical ranking.
• A firm's tier, rather than its alphabetical position within Tier II or Tier III, should therefore be used when describing its standing.

Referencing the ranking

Depending on the firm's published tier, appropriate factual descriptions may include:

• Tier I: “Ranked Tier I” or “Ranked among the Top 5”
• Tier II: “Ranked Tier II” or “Ranked among the Top 15”
• Tier III: “Ranked Tier III” or “Ranked among the Top 30”

Firms should not describe an alphabetical position within Tier II or Tier III as a specific numerical rank.

Use of The Economy Rankings recognition materials

Editorial inclusion in a ranking does NOT by itself grant permission to use The Economy Rankings badges, seals, logos, official recognition graphics, licensed quotations, or other proprietary recognition materials.

Organizations wishing to use official The Economy Rankings recognition materials in corporate websites, marketing materials, investor communications, client presentations, social media, press releases, or other external communications should refer to the applicable licensing terms and usage policies:

• The Economy Rankings License Structure — available licence levels and permitted recognition uses
  Rankings License Structure | The Economy
• The Economy Rankings License Policy — licensing conditions governing use of The Economy Rankings recognition, marks, and related materials
  The Economy Rankings License Policy | The Economy
• Recognition Use Guide — guidance on permitted wording, presentation, attribution, and use of ranking recognition
  Recognition Use Guide | The Economy

Ranking inclusion remains editorially independent regardless of whether an organization purchases or holds a recognition-materials licence.

Recognized institutions may reference the designation in:

• corporate websites
• investor communications
• marketing materials
• client presentations

Licensing inquiries:
[email protected]